Rx vaistinė - Company finances
|
EUR
|
2019
From: 2019-02-04
To: 2019-12-31
|
2020
From: 2020-01-01
To: 2020-12-31
|
2021
From: 2021-01-01
To: 2021-12-31
|
2022
From: 2022-01-01
To: 2022-12-31
|
2023
From: 2023-01-01
To: 2023-12-31
|
2024
From: 2024-01-01
To: 2024-12-31
|
2025
From: 2025-01-01
To: 2025-12-31
|
|---|---|---|---|---|---|---|---|
|
Financial data
|
|||||||
| Sales revenue | - | - | - | - | 117,045 | 2,745,206 | 9,799,809 |
| Profit before tax | -6 | -45 | -92 | -55 | 69,966 | 1,125 | 99,708 |
| Net profit | -6 | -45 | -92 | -55 | 59,246 | -1,159 | 78,915 |
| Equity | 2,494 | 2,449 | 2,357 | 2,302 | 61,548 | 60,389 | 139,304 |
| Liabilities | 0 | 0 | 0 | 0 | 19,893 | 1,165,622 | 1,587,563 |
| Non-current assets | 0 | 0 | 0 | 0 | 0 | 68,854 | 60,583 |
| Current assets | 994 | 949 | 857 | 802 | 81,441 | 1,153,426 | 1,796,607 |
| Total assets | 994 | 949 | 857 | 802 | 81,441 | 1,222,280 | 1,857,190 |
|
Taxes paid
|
|||||||
| STI taxes | - | - | - | - | 10,074 | 31,099 | 43,737 |
| Social insurance contributions | - | - | - | - | - | 35,470 | 74,640 |
|
Financial indicators
|
|||||||
| Revenue change y/y | - | - | - | - | - | +2245.4% | +257.0% |
| ROA Return on Assets (ROA). The ratio of net profit to assets. Indicates the company's efficiency. | -0.6% | -4.7% | -10.7% | -6.9% | 72.7% | -0.1% | 4.2% |
| ROE Return on equity. The ratio of net profit to equity. Shows the return to shareholders. | -0.2% | -1.8% | -3.9% | -2.4% | 96.3% | -1.9% | 56.6% |
| Profit margin Net profit margin. Shows the overall profitability of the company. | - | - | - | - | 50.6% | 0.0% | 0.8% |
| EBT% EBT (Earnings Before Taxes) to revenue ratio. Shows the overall profitability of the company. | - | - | - | - | 59.8% | 0.0% | 1.0% |
| Liabilities/Equity The debt-to-equity ratio shows the company's capital structure. | - | - | - | - | 0.3 | 19.3 | 11.4 |
| Revenue per employee Ratio of revenue to the average annual number of employees. Indicates company efficiency. | - | - | - | - | 52,020 | 567,978 | 1,175,982 |
Sales revenue
See Scoris data in Google Search
Mark Scoris as a favorite source. One click, no registration.
Rx vaistinė - Social security debts
| From | To | Debt, € |
|---|---|---|
| 2024-05-16 | 2024-05-19 | 0.02 |
| 2024-04-23 | 2024-05-08 | 0.02 |
Rx vaistinė - VMI tax arrears
The company had no tax arrears (debts) to the State Tax Inspectorate
VMI debt information has been collected since 2024-10-07. Debts for older periods will not be displayed.
Analysis of the company's financial position
This description was generated by artificial intelligence.
Report if inaccurate.
Rx vaistine, UAB (Private Limited Liability Company, code 305010439) operates in the retail sale of pharmaceutical products. In 2025, revenue reached €9.80M, increasing by 257.0% year on year from 2024. Net profit was €78.9K and the profit margin was 0.8%, showing that profitability remained thin despite the much larger sales base. The company’s performance has been volatile over the last three years: it earned €59.2K in net profit on €117.0K revenue in 2023, moved close to break-even in 2024, and then returned to profit in 2025. Total assets rose to €1.86M in 2025, with equity of €139.3K and liabilities of €1.59M. Short-term assets accounted for most of the balance sheet at €1.80M, while long-term assets were €60.6K. Efficiency indicators were strong, with asset turnover at 5.28x and revenue per employee at €1.22M. The balance sheet also indicates a high level of leverage, as liabilities were far above equity at year-end 2025.